Corvus Pharmaceuticals Inc (CRVS) Unusual Options Activity Today

Checking CRVS unusual options activity helps you spot when traders are making outsized bets on Corvus Pharmaceuticals Inc before the broader market catches on. Corvus Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor CRVS unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching CRVS unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CRVS unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and CRVS unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.

Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Catalysts rarely arrive without a footprint, and CRVS unusual options activity is often where that footprint shows up first. Our scanner tracks Corvus Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at CRVS unusual options volume on the call side or chasing put sweeps, Corvus Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.